The Investor Relations website contains information about KalVista Pharmaceuticals's business for stockholders, potential investors, and financial analysts.
KalVista is advancing science to empower everyday lives with innovative oral medicines. KalVista's mission begins with hereditary angioedema, HAE.
Common Stock (KALV) including earnings per share, earnings forecasts at Nasdaq ... Investor Relations Intelligence. Featured ... Common Stock (KALV) Earnings. Data ...
People also ask
Is Kalv a buy or sell?
This information can be used by investors to verify and understand the financial position of the company. Many, but not all SEC filings are available in the ...
“Investor” has the meaning set forth in the Preamble. [***]Confidential Treatment Requested. 2. “Investor Controlled Entity ...
Missing: relations | Show results with:relations
Rating
(3,975)
KalVista Pharmaceuticals (KALV) will release its next earnings report on Jul 3, 2024. In the last quarter KalVista Pharmaceuticals reported -$0.747 EPS in ...
Missing: relations | Show results with:relations
3 days ago · Find the latest KalVista Pharmaceuticals, Inc. (KALV) stock ... stock trading and investing ... Periodic Financial Reports. Proxy Statements.